Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
OCCIDENT is a venture capital organization founded in 2012, with offices in Munich, Germany, and Zug, Switzerland. The firm focuses on investing in deep-tech startups, particularly those that emerge as spin-offs from scientific research. OCCIDENT aims to create tangible impact by providing concrete solutions to various societal challenges, particularly in the healthcare and biotech sectors.
As of now, OCCIDENT manages a portfolio of nine companies, emphasizing its commitment to supporting early-stage ventures. The organization collaborates closely with founding teams to ensure sustainable success potential in their investments. This approach not only enhances the growth prospects of the startups but also aligns with OCCIDENT's mission to address pressing societal issues through innovative technologies.
OCCIDENT has established itself as a key player in the European venture capital landscape, focusing on sectors that promise significant advancements in medical technology and sustainable practices. The firm’s notable milestones include successful investments in companies that are pioneering solutions in healthcare and biotechnology.
OCCIDENT invests primarily in deep-tech startups at the seed financing stage, with a strong emphasis on healthcare and biotech sectors. The organization seeks companies that demonstrate sustainable success potential, which is a critical criterion in their investment decisions. OCCIDENT's investment strategy is rooted in collaboration, as they work closely with founding teams to provide support and guidance throughout the development process.
The firm is particularly interested in startups that are spin-offs from scientific research, as these ventures often possess unique insights and innovative technologies. OCCIDENT's focus on sustainable solutions reflects its commitment to addressing societal challenges, making it an attractive partner for entrepreneurs in the deep-tech space. The organization typically invests in companies that are developing groundbreaking technologies aimed at improving health outcomes and enhancing quality of life.
OCCIDENT's portfolio includes a diverse range of companies that are making significant strides in healthcare and technology:
These companies exemplify OCCIDENT's commitment to investing in innovative solutions that address critical health challenges and improve patient outcomes.
Patrizia: CEO of OCCIDENT, brings extensive experience in venture capital and a strong background in healthcare investments.
Michael: Investment Manager, specializes in identifying promising deep-tech startups and has a track record of successful investments in the biotech sector.
Team Member: Lifesciences Lead, focuses on guiding portfolio companies in the healthcare space, leveraging expertise in medical technologies.
Team Member: Lifesciences Specialist, provides support in evaluating potential investments and assisting portfolio companies with strategic growth.
Team Member: Legal Counsel, ensures compliance and manages legal aspects of investments and partnerships.
Team Member: Finance and Administration, oversees financial operations and reporting for the organization.
Team Member: Office Manager, coordinates day-to-day operations and supports the team in various administrative tasks.
Startups interested in pitching to OCCIDENT should send their proposals via email to office@occident.group. The pitch deck should include a comprehensive overview of the business model, market analysis, and the founding team's background. OCCIDENT appreciates clear and concise presentations that outline the startup's vision and potential impact.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In recent months, OCCIDENT has continued to expand its portfolio, adding innovative companies such as Lymphatica and Altavo, which focus on healthcare solutions. The firm remains active in the European venture capital scene, seeking out startups that align with its mission of addressing societal challenges through deep-tech investments.
OCCIDENT has also been involved in discussions regarding potential partnerships with other venture capital firms to enhance its investment capabilities and broaden its reach within the deep-tech sector.
What are OCCIDENT's investment criteria?
OCCIDENT focuses on deep-tech startups at the seed financing stage, particularly in the healthcare and biotech sectors. The firm seeks companies with sustainable success potential and those that are often spin-offs from scientific research.
How can startups apply or pitch to OCCIDENT?
Startups can pitch to OCCIDENT by sending an email to office@occident.group. It is advisable to include a detailed business plan and information about the founding team.
What makes OCCIDENT different from other venture capital firms?
OCCIDENT emphasizes collaboration with founding teams and focuses on sustainable solutions that address societal challenges. Their commitment to deep-tech investments sets them apart in the venture capital landscape.
What is OCCIDENT's geographic scope?
The firm primarily operates in Europe, investing in startups that are based in or have a significant presence in the region.
What is OCCIDENT's approach to post-investment involvement?
OCCIDENT collaborates closely with its portfolio companies, providing support and guidance to help them achieve their growth objectives and navigate challenges.
What is the typical check size for OCCIDENT's investments?
While specific check sizes are not disclosed, OCCIDENT focuses on seed-stage investments, which typically range from €100,000 to €1 million.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.